Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Earnings
Amylyx reports Q3 EPS (92c), consensus (97c) » 16:06
11/10/22
11/10
16:06
11/10/22
16:06
AMLX

Amylyx

$35.96 /

+1.26 (+3.63%)

Reports Q3 revenue $345K,…

Reports Q3 revenue $345K, consensus $80K. "The third quarter has proven to be a transformative time for Amylyx and the ALS community, marked by the regulatory approval of our new oral therapy for the treatment of ALS in the United States and commercial availability of our first product in Canada," said Joshua Cohen and Justin Klee, Co-CEOs. "We are thrilled that RELYVRIO and ALBRIOZA are now available to people living with ALS in the U.S. and Canada, and we are encouraged by the early trajectory of enrollment in our Amylyx Care Team (ACT) Support Program as well as the rate of new prescriptions for this important new therapeutic option. We continue to work expeditiously during the early stages of our commercial launch to ensure every eligible person living with ALS will gain access as quickly and efficiently as possible."

ShowHide Related Items >><<
AMLX Amylyx
$35.96 /

+1.26 (+3.63%)

AMLX Amylyx
$35.96 /

+1.26 (+3.63%)

10/24/22 H.C. Wainwright
Amylyx price target raised to $50 from $35 at H.C. Wainwright
10/03/22 Citi
Citi ups Amylyx target, sees buying opportunity after selloff
09/08/22 SVB Securities
Amylyx price target raised to $50 from $31 at SVB Securities
09/08/22 Citi
Amylyx shares should rally $20 or more today, says Citi
AMLX Amylyx
$35.96 /

+1.26 (+3.63%)

  • 07
    Oct
  • 07
    Jan
AMLX Amylyx
$35.96 /

+1.26 (+3.63%)

AMLX Amylyx
$35.96 /

+1.26 (+3.63%)

AMLX Amylyx
$35.96 /

+1.26 (+3.63%)

Options
Amylyx Pharmaceuticals options imply 5.0% move in share price post-earnings » 14:49
11/10/22
11/10
14:49
11/10/22
14:49
AMLX

Amylyx

$36.25 /

+1.545 (+4.45%)

Pre-earnings options…

Pre-earnings options volume in Amylyx Pharmaceuticals is normal with puts leading calls 7:3. Implied volatility suggests the market is anticipating a move near 5.0%, or $1.82, after results are released. Median move over the past eight quarters is 9.1%.

ShowHide Related Items >><<
AMLX Amylyx
$36.25 /

+1.545 (+4.45%)

AMLX Amylyx
$36.25 /

+1.545 (+4.45%)

10/24/22 H.C. Wainwright
Amylyx price target raised to $50 from $35 at H.C. Wainwright
10/03/22 Citi
Citi ups Amylyx target, sees buying opportunity after selloff
09/08/22 SVB Securities
Amylyx price target raised to $50 from $31 at SVB Securities
09/08/22 Citi
Amylyx shares should rally $20 or more today, says Citi
AMLX Amylyx
$36.25 /

+1.545 (+4.45%)

  • 07
    Oct
  • 07
    Jan
AMLX Amylyx
$36.25 /

+1.545 (+4.45%)

AMLX Amylyx
$36.25 /

+1.545 (+4.45%)

AMLX Amylyx
$36.25 /

+1.545 (+4.45%)

Over a month ago
Recommendations
Amylyx price target raised to $50 from $35 at H.C. Wainwright » 06:04
10/24/22
10/24
06:04
10/24/22
06:04
AMLX

Amylyx

$36.26 /

+0.35 (+0.97%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Andrew Fein raised the firm's price target on Amylyx Pharmaceuticals to $50 from $35 and keeps a Buy rating on the shares. The analyst says the PHOENIX study "might show strong convincing data both concerning the functional endpoint, and survival."

ShowHide Related Items >><<
AMLX Amylyx
$36.26 /

+0.35 (+0.97%)

AMLX Amylyx
$36.26 /

+0.35 (+0.97%)

10/03/22 Citi
Citi ups Amylyx target, sees buying opportunity after selloff
09/08/22 SVB Securities
Amylyx price target raised to $50 from $31 at SVB Securities
09/08/22 Citi
Amylyx shares should rally $20 or more today, says Citi
07/06/22 Citi
Amylyx price target raised to $37 from $33 at Citi
AMLX Amylyx
$36.26 /

+0.35 (+0.97%)

  • 07
    Oct
  • 07
    Jan
AMLX Amylyx
$36.26 /

+0.35 (+0.97%)

AMLX Amylyx
$36.26 /

+0.35 (+0.97%)

AMLX Amylyx
$36.26 /

+0.35 (+0.97%)

Options
Largest borrow rate increases among liquid names » 08:45
10/20/22
10/20
08:45
10/20/22
08:45
BCTX

BriaCell

$5.83 /

-0.41 (-6.57%)

, DIA

SPDR Dow Jones Industrial Average ETF Trust

$304.37 /

-1.11 (-0.36%)

, DICE

Dice Therapeutics

$33.65 /

-0.365 (-1.07%)

, DNMR

Danimer Scientific

$2.28 /

-0.115 (-4.81%)

, APRN

Blue Apron

$2.33 /

-0.11 (-4.51%)

, AMLX

Amylyx

$35.69 /

-0.56 (-1.54%)

, EWW

iShares MSCI Mexico

$46.03 /

-0.24 (-0.52%)

, LCID

Lucid Group

$12.65 /

-0.36 (-2.77%)

, TIGR

UP Fintech

$3.43 /

-0.11 (-3.11%)

, HIVE

Hive Blockchain

$3.15 /

-0.06 (-1.87%)

Latest data shows the…

Latest data shows the largest indicative borrow rate increases among liquid option names include: BriaCell Therapeutics (BCTX) 25.79% +1.52, SPDR DJIA ETF (DIA) 1.74% +1.33, Dice Therapeutics (DICE) 4.80% +0.71, Danimer Scientific (DNMR) 17.02% +0.70, Blue Apron (APRN) 25.16% +0.52, Amylyx Pharmaceuticals (AMLX) 6.11% +0.38, EWW (EWW) 3.20% +0.33, Lucid Group (LCID) 11.42% +0.27, UP Fintech Holding Ltd (TIGR) 32.03% +0.27, and HIVE Blockchain (HIVE) 14.52% +0.27.

ShowHide Related Items >><<
TIGR UP Fintech
$3.43 /

-0.11 (-3.11%)

LCID Lucid Group
$12.65 /

-0.36 (-2.77%)

HIVE Hive Blockchain
$3.15 /

-0.06 (-1.87%)

DNMR Danimer Scientific
$2.28 /

-0.115 (-4.81%)

DICE Dice Therapeutics
$33.65 /

-0.365 (-1.07%)

DIA SPDR Dow Jones Industrial Average ETF Trust
$304.37 /

-1.11 (-0.36%)

BCTX BriaCell
$5.83 /

-0.41 (-6.57%)

APRN Blue Apron
$2.33 /

-0.11 (-4.51%)

AMLX Amylyx
$35.69 /

-0.56 (-1.54%)

BCTX BriaCell
$5.83 /

-0.41 (-6.57%)

02/14/22 H.C. Wainwright
BriaCell initiated with a Buy at H.C. Wainwright
DIA SPDR Dow Jones Industrial Average ETF Trust
$304.37 /

-1.11 (-0.36%)

DICE Dice Therapeutics
$33.65 /

-0.365 (-1.07%)

10/11/22 BofA
Dice Therapeutics price target raised to $62 from $34 at BofA
10/11/22 SVB Securities
Dice Therapeutics price target raised to $77 from $46 at SVB Securities
10/11/22 H.C. Wainwright
Dice Therapeutics price target raised to $60 from $40 at H.C. Wainwright
10/11/22 Cantor Fitzgerald
Dice Therapeutics price target raised to $68 from $36 at Cantor Fitzgerald
DNMR Danimer Scientific
$2.28 /

-0.115 (-4.81%)

10/12/22 Piper Sandler
Danimer Scientific initiated with an Overweight at Piper Sandler
11/16/21 Jefferies
Danimer Scientific price target lowered to $30 from $34 at Jefferies
APRN Blue Apron
$2.33 /

-0.11 (-4.51%)

08/10/22 Lake Street
Blue Apron initiated with a Buy at Lake Street
07/20/22 Benchmark
Benchmark starts Blue Apron at Buy with turnaround not getting credit
07/20/22 Benchmark
Blue Apron initiated with a Buy at Benchmark
05/10/22 Canaccord
Blue Apron price target lowered to $10 from $12 at Canaccord
AMLX Amylyx
$35.69 /

-0.56 (-1.54%)

10/03/22 Citi
Citi ups Amylyx target, sees buying opportunity after selloff
09/08/22 SVB Securities
Amylyx price target raised to $50 from $31 at SVB Securities
09/08/22 Citi
Amylyx shares should rally $20 or more today, says Citi
07/06/22 Citi
Amylyx price target raised to $37 from $33 at Citi
EWW iShares MSCI Mexico
$46.03 /

-0.24 (-0.52%)

LCID Lucid Group
$12.65 /

-0.36 (-2.77%)

09/27/22 Cantor Fitzgerald
Lucid Group initiated with an Overweight at Cantor Fitzgerald
09/27/22 Cantor Fitzgerald
Lucid Group initiated with an Overweight at Cantor Fitzgerald
09/15/22 Citi
Lucid Group resumed with a Buy at Citi
09/14/22 Needham
Needham starts Lucid Group at Underperform on lack of profitability
TIGR UP Fintech
$3.43 /

-0.11 (-3.11%)

06/13/22 Daiwa
UP Fintech price target raised to $5.70 from $5.40 at Daiwa
05/19/22 China Renaissance
UP Fintech assumed with Hold from Buy at China Renaissance
12/01/21 Citi
UP Fintech price target lowered to $7.58 from $18.22 at Citi
10/29/21 Alliance Global Partners
MICT could benefit on top China brokers' fallout, says Alliance Global Partners
HIVE Hive Blockchain
$3.15 /

-0.06 (-1.87%)

08/29/22 Canaccord
Hive Blockchain price target raised to $7 from $5.50 at Canaccord
08/18/22 H.C. Wainwright
Hive Blockchain price target raised to $7 from $6 at H.C. Wainwright
08/04/22 H.C. Wainwright
Hive Blockchain price target raised to $6 from $5 at H.C. Wainwright
07/25/22 Canaccord
Hive Blockchain price target lowered to $5.50 from $14 at Canaccord
LCID Lucid Group
$12.65 /

-0.36 (-2.77%)

DNMR Danimer Scientific
$2.28 /

-0.115 (-4.81%)

APRN Blue Apron
$2.33 /

-0.11 (-4.51%)

AMLX Amylyx
$35.69 /

-0.56 (-1.54%)

  • 13
    Oct
  • 07
    Oct
  • 07
    Jan
LCID Lucid Group
$12.65 /

-0.36 (-2.77%)

DIA SPDR Dow Jones Industrial Average ETF Trust
$304.37 /

-1.11 (-0.36%)

APRN Blue Apron
$2.33 /

-0.11 (-4.51%)

AMLX Amylyx
$35.69 /

-0.56 (-1.54%)

LCID Lucid Group
$12.65 /

-0.36 (-2.77%)

DICE Dice Therapeutics
$33.65 /

-0.365 (-1.07%)

APRN Blue Apron
$2.33 /

-0.11 (-4.51%)

AMLX Amylyx
$35.69 /

-0.56 (-1.54%)

TIGR UP Fintech
$3.43 /

-0.11 (-3.11%)

LCID Lucid Group
$12.65 /

-0.36 (-2.77%)

HIVE Hive Blockchain
$3.15 /

-0.06 (-1.87%)

EWW iShares MSCI Mexico
$46.03 /

-0.24 (-0.52%)

DNMR Danimer Scientific
$2.28 /

-0.115 (-4.81%)

DIA SPDR Dow Jones Industrial Average ETF Trust
$304.37 /

-1.11 (-0.36%)

BCTX BriaCell
$5.83 /

-0.41 (-6.57%)

APRN Blue Apron
$2.33 /

-0.11 (-4.51%)

AMLX Amylyx
$35.69 /

-0.56 (-1.54%)

DIA SPDR Dow Jones Industrial Average ETF Trust
$304.37 /

-1.11 (-0.36%)

Syndicate
Amylyx 6.69M share Secondary priced at $32.00 » 06:11
10/07/22
10/07
06:11
10/07/22
06:11
AMLX

Amylyx

$32.80 /

+3.07 (+10.33%)

The deal size was…

The deal size was increased to 6.69M shares from 6.0M shares and priced below last closing price of $32.82. Goldman Sachs, BofA, SVB Securities and Evercore ISI are acting as joint book running managers for the offering.

ShowHide Related Items >><<
AMLX Amylyx
$32.80 /

+3.07 (+10.33%)

AMLX Amylyx
$32.80 /

+3.07 (+10.33%)

10/03/22 Citi
Citi ups Amylyx target, sees buying opportunity after selloff
09/08/22 SVB Securities
Amylyx price target raised to $50 from $31 at SVB Securities
09/08/22 Citi
Amylyx shares should rally $20 or more today, says Citi
07/06/22 Citi
Amylyx price target raised to $37 from $33 at Citi
AMLX Amylyx
$32.80 /

+3.07 (+10.33%)

  • 07
    Oct
  • 07
    Jan
AMLX Amylyx
$32.80 /

+3.07 (+10.33%)

AMLX Amylyx
$32.80 /

+3.07 (+10.33%)

AMLX Amylyx
$32.80 /

+3.07 (+10.33%)

On The Fly
Fly Intel: After-Hours Movers » 17:59
10/04/22
10/04
17:59
10/04/22
17:59
SAR

Saratoga Investment

$21.80 /

+0.88 (+4.21%)

, EMR

Emerson Electric

$78.21 /

+2.685 (+3.56%)

, BX

Blackstone

$93.52 /

+7.08 (+8.19%)

, GOGL

Golden Ocean

$8.17 /

+0.415 (+5.35%)

, YEXT

Yext

$4.77 /

+0.34 (+7.67%)

, ICVX

Icosavax

$3.21 /

+0.13 (+4.22%)

, SGH

SGH

$17.00 /

+0.97 (+6.05%)

, KORE

Kore Group

$2.23 /

+0.21 (+10.40%)

, NVRO

Nevro

$49.29 /

+1.84 (+3.88%)

, BRSP

BrightSpire Capital

$6.96 /

+0.54 (+8.41%)

, AMLX

Amylyx

$31.12 /

+1.4 (+4.71%)

Check out this evening's…

ShowHide Related Items >><<
YEXT Yext
$4.77 /

+0.34 (+7.67%)

SGH SGH
$17.00 /

+0.97 (+6.05%)

SAR Saratoga Investment
$21.80 /

+0.88 (+4.21%)

NVRO Nevro
$49.29 /

+1.84 (+3.88%)

KORE Kore Group
$2.23 /

+0.21 (+10.40%)

ICVX Icosavax
$3.21 /

+0.13 (+4.22%)

GOGL Golden Ocean
$8.17 /

+0.415 (+5.35%)

EMR Emerson Electric
$78.21 /

+2.685 (+3.56%)

BX Blackstone
$93.52 /

+7.08 (+8.19%)

BRSP BrightSpire Capital
$6.96 /

+0.54 (+8.41%)

AMLX Amylyx
$31.12 /

+1.4 (+4.71%)

SAR Saratoga Investment
$21.80 /

+0.88 (+4.21%)

10/07/21 B. Riley
Saratoga Investment price target raised to $31 from $30 at B. Riley
EMR Emerson Electric
$78.21 /

+2.685 (+3.56%)

10/03/22 Barclays
Emerson Electric price target lowered to $80 from $82 at Barclays
09/12/22 Citi
Citi opens 'positive Catalyst Watch' on MasTec, Emerson Electric
08/16/22 Wolfe Research
Aspen Technology initiated with a Peer Perform at Wolfe Research
08/16/22 Bernstein
Emerson Electric assumed with a Market Perform at Bernstein
BX Blackstone
$93.52 /

+7.08 (+8.19%)

08/31/22 Barclays
Blackstone initiated with an Overweight at Barclays
08/12/22 Deutsche Bank
Blackstone price target raised to $153 from $147 at Deutsche Bank
07/25/22 Piper Sandler
Blackstone price target lowered to $120 from $154 at Piper Sandler
07/24/22 Keefe Bruyette
Blackstone downgraded to Market Perform from Outperform at Keefe Bruyette
GOGL Golden Ocean
$8.17 /

+0.415 (+5.35%)

09/26/22 Jefferies
Golden Ocean downgraded to Hold from Buy at Jefferies
07/20/22 Jefferies
Golden Ocean initiated with a Buy at Jefferies
05/20/22 Kepler Cheuvreux
Golden Ocean downgraded to Hold from Buy at Kepler Cheuvreux
05/20/22 H.C. Wainwright
Golden Ocean price target raised to $18 from $13 at H.C. Wainwright
YEXT Yext
$4.77 /

+0.34 (+7.67%)

09/08/22 MKM Partners
Yext price target lowered to $6 from $8 at MKM Partners
03/10/22 MKM Partners
Yext price target lowered to $8 from $17 at MKM Partners
03/09/22 DA Davidson
Yext downgraded to Neutral from Buy at DA Davidson
03/09/22 Needham
Yext downgraded to Hold from Buy at Needham
ICVX Icosavax
$3.21 /

+0.13 (+4.22%)

06/29/22 Evercore ISI
Icosavax upgraded to Outperform at Evercore on 'competitive' RSV vaccine data
06/29/22 Evercore ISI
Icosavax upgraded to Outperform from In Line at Evercore ISI
03/25/22 Evercore ISI
Evercore downgrades Icosavax amid 60% selloff after 'big error'
03/25/22 Evercore ISI
Icosavax downgraded to In Line from Outperform at Evercore ISI
SGH SGH
$17.00 /

+0.97 (+6.05%)

06/30/22 Needham
SGH price target lowered to $40 from $45 at Needham
06/30/22 Stifel
SGH price target lowered to $32 from $45 at Stifel
06/30/22 Deutsche Bank
SGH price target lowered to $32 from $40 at Deutsche Bank
06/30/22 Barclays
SGH price target lowered to $22 from $30 at Barclays
KORE Kore Group
$2.23 /

+0.21 (+10.40%)

08/12/22 Cowen
Kore Group price target lowered to $9 from $12.50 at Cowen
05/17/22 Deutsche Bank
Kore Group price target lowered to $6 from $7.50 at Deutsche Bank
04/12/22 Morgan Stanley
Kore Group price target lowered to $6.50 from $7.50 at Morgan Stanley
04/12/22 Morgan Stanley
Morgan Stanley cuts Telecom & Networking Equipment industry view to Cautious
NVRO Nevro
$49.29 /

+1.84 (+3.88%)

10/03/22 Piper Sandler
AACE guideline update positive for Nevro, says Piper Sandler
09/01/22 Piper Sandler
Piper stays on sidelines of Nevro despite 'handful of positive updates'
08/04/22 Piper Sandler
Nevro price target lowered to $45 from $64 at Piper Sandler
08/01/22 Piper Sandler
Nevro successfully defended exclusive SCS ability, says Piper Sandler
BRSP BrightSpire Capital
$6.96 /

+0.54 (+8.41%)

03/11/22 BTIG
BrightSpire Capital coverage transferred at BTIG
02/18/22 BofA
BrightSpire Capital initiated with a Neutral at BofA
01/04/22 B. Riley
BrightSpire Capital shares can return 35%, says at B. Riley
12/17/21 JMP Securities
BrightSpire Capital initiated with an Outperform at JMP Securities
AMLX Amylyx
$31.12 /

+1.4 (+4.71%)

10/03/22 Citi
Citi ups Amylyx target, sees buying opportunity after selloff
09/08/22 SVB Securities
Amylyx price target raised to $50 from $31 at SVB Securities
09/08/22 Citi
Amylyx shares should rally $20 or more today, says Citi
07/06/22 Citi
Amylyx price target raised to $37 from $33 at Citi
YEXT Yext
$4.77 /

+0.34 (+7.67%)

SGH SGH
$17.00 /

+0.97 (+6.05%)

SAR Saratoga Investment
$21.80 /

+0.88 (+4.21%)

NVRO Nevro
$49.29 /

+1.84 (+3.88%)

KORE Kore Group
$2.23 /

+0.21 (+10.40%)

ICVX Icosavax
$3.21 /

+0.13 (+4.22%)

GOGL Golden Ocean
$8.17 /

+0.415 (+5.35%)

EMR Emerson Electric
$78.21 /

+2.685 (+3.56%)

BX Blackstone
$93.52 /

+7.08 (+8.19%)

BRSP BrightSpire Capital
$6.96 /

+0.54 (+8.41%)

AMLX Amylyx
$31.12 /

+1.4 (+4.71%)

  • 07
    Jan
  • 08
    Dec
EMR Emerson Electric
$78.21 /

+2.685 (+3.56%)

BX Blackstone
$93.52 /

+7.08 (+8.19%)

AMLX Amylyx
$31.12 /

+1.4 (+4.71%)

YEXT Yext
$4.77 /

+0.34 (+7.67%)

SGH SGH
$17.00 /

+0.97 (+6.05%)

NVRO Nevro
$49.29 /

+1.84 (+3.88%)

ICVX Icosavax
$3.21 /

+0.13 (+4.22%)

GOGL Golden Ocean
$8.17 /

+0.415 (+5.35%)

EMR Emerson Electric
$78.21 /

+2.685 (+3.56%)

BX Blackstone
$93.52 /

+7.08 (+8.19%)

AMLX Amylyx
$31.12 /

+1.4 (+4.71%)

SGH SGH
$17.00 /

+0.97 (+6.05%)

GOGL Golden Ocean
$8.17 /

+0.415 (+5.35%)

BX Blackstone
$93.52 /

+7.08 (+8.19%)

AMLX Amylyx
$31.12 /

+1.4 (+4.71%)

Syndicate
Amylyx announces offering of 6M shares of common stock » 16:30
10/04/22
10/04
16:30
10/04/22
16:30
AMLX

Amylyx

$31.12 /

+1.4 (+4.71%)

Amylyx Pharmaceuticals…

Amylyx Pharmaceuticals announced the launch of an underwritten public offering of 6M shares of common stock pursuant to a registration statement on Form S-1 filed with the SEC. Goldman Sachs, BofA Securities, SVB Securities, and Evercore ISI are acting as joint book-running managers for the proposed offering. H.C. Wainwright & Co. is acting as lead manager for the proposed offering.

ShowHide Related Items >><<
AMLX Amylyx
$31.12 /

+1.4 (+4.71%)

AMLX Amylyx
$31.12 /

+1.4 (+4.71%)

10/03/22 Citi
Citi ups Amylyx target, sees buying opportunity after selloff
09/08/22 SVB Securities
Amylyx price target raised to $50 from $31 at SVB Securities
09/08/22 Citi
Amylyx shares should rally $20 or more today, says Citi
07/06/22 Citi
Amylyx price target raised to $37 from $33 at Citi
AMLX Amylyx
$31.12 /

+1.4 (+4.71%)

  • 07
    Jan
AMLX Amylyx
$31.12 /

+1.4 (+4.71%)

AMLX Amylyx
$31.12 /

+1.4 (+4.71%)

AMLX Amylyx
$31.12 /

+1.4 (+4.71%)

Syndicate
Amylyx files to sell 6M shares of common stock  16:09
10/04/22
10/04
16:09
10/04/22
16:09
AMLX

Amylyx

$31.12 /

+1.4 (+4.71%)

 
ShowHide Related Items >><<
AMLX Amylyx
$31.12 /

+1.4 (+4.71%)

AMLX Amylyx
$31.12 /

+1.4 (+4.71%)

10/03/22 Citi
Citi ups Amylyx target, sees buying opportunity after selloff
09/08/22 SVB Securities
Amylyx price target raised to $50 from $31 at SVB Securities
09/08/22 Citi
Amylyx shares should rally $20 or more today, says Citi
07/06/22 Citi
Amylyx price target raised to $37 from $33 at Citi
AMLX Amylyx
$31.12 /

+1.4 (+4.71%)

  • 07
    Jan
AMLX Amylyx
$31.12 /

+1.4 (+4.71%)

AMLX Amylyx
$31.12 /

+1.4 (+4.71%)

AMLX Amylyx
$31.12 /

+1.4 (+4.71%)

Recommendations
Citi ups Amylyx target, sees buying opportunity after selloff » 06:35
10/03/22
10/03
06:35
10/03/22
06:35
AMLX

Amylyx

$28.18 /

-1.96 (-6.50%)

Citi analyst Neena…

Citi analyst Neena Bitritto-Garg raised the firm's price target on Amylyx Pharmaceuticals to $50 from $48 and keeps a Buy rating on the shares. The analyst updated her model on full FDA approval for AMX0035, now Relyvrio. The final net price of $158,000 per year, below the $170,000 price for edaravone, "should enable rapid payer discussions and garner goodwill from physicians/patient advocacy groups, driving rapid uptake in demand and sales recognition," Bitritto-Garg tells investors in a research note. The analyst says continued weakness in the shares on financing overhang and the PHOENIX readout concerns "sets up an attractive upside into initial launch numbers" and European approval. Bitritto-Garg sees a buying opportunity at current Amylyx shared levels.

ShowHide Related Items >><<
AMLX Amylyx
$28.18 /

-1.96 (-6.50%)

AMLX Amylyx
$28.18 /

-1.96 (-6.50%)

09/08/22 SVB Securities
Amylyx price target raised to $50 from $31 at SVB Securities
09/08/22 Citi
Amylyx shares should rally $20 or more today, says Citi
07/06/22 Citi
Amylyx price target raised to $37 from $33 at Citi
06/14/22 Citi
Amylyx price target raised to $33 from $32 at Citi
AMLX Amylyx
$28.18 /

-1.96 (-6.50%)

  • 07
    Jan
AMLX Amylyx
$28.18 /

-1.96 (-6.50%)

AMLX Amylyx
$28.18 /

-1.96 (-6.50%)

AMLX Amylyx
$28.18 /

-1.96 (-6.50%)

Options
Unusually active option classes on open September 30th » 09:40
09/30/22
09/30
09:40
09/30/22
09:40
QUAD

Quad/Graphics

/

+

, WSM

Williams-Sonoma

/

+

, INDA

iShares MSCI India ETF

/

+

, AMLX

Amylyx

/

+

, AVCT

AVCtechnologies

/

+

, NCLH

Norwegian Cruise Line

/

+

, GILD

Gilead

/

+

, LULU

Lululemon

/

+

, LI

Li Auto

/

+

, APRN

Blue Apron

/

+

Unusual total active…

Unusual total active option classes on open include: Quad Graphics (QUAD), Williams Sonoma (WSM), iShares MSCI India (INDA), Amylyx Pharmaceuticals (AMLX), American Virtual Cloud Technologies (AVCT), Norwegian Cruise Lines (NCLH), Gilead (GILD), Lululemon (LULU), Li Auto (LI), and Blue Apron (APRN).

ShowHide Related Items >><<
WSM Williams-Sonoma
/

+

QUAD Quad/Graphics
/

+

NCLH Norwegian Cruise Line
/

+

LULU Lululemon
/

+

LI Li Auto
/

+

GILD Gilead
/

+

AVCT AVCtechnologies
/

+

APRN Blue Apron
/

+

AMLX Amylyx
/

+

QUAD Quad/Graphics
/

+

WSM Williams-Sonoma
/

+

09/23/22 UBS
Williams-Sonoma assumed with a Sell at UBS
08/25/22 Wedbush
Williams-Sonoma price target raised to $190 from $155 at Wedbush
08/25/22 UBS
Williams-Sonoma price target raised to $110 from $100 at UBS
08/25/22 Baird
Williams-Sonoma price target raised to $170 from $145 at Baird
INDA iShares MSCI India ETF
/

+

AMLX Amylyx
/

+

09/08/22 SVB Securities
Amylyx price target raised to $50 from $31 at SVB Securities
09/08/22 Citi
Amylyx shares should rally $20 or more today, says Citi
07/06/22 Citi
Amylyx price target raised to $37 from $33 at Citi
06/14/22 Citi
Amylyx price target raised to $33 from $32 at Citi
AVCT AVCtechnologies
/

+

NCLH Norwegian Cruise Line
/

+

09/20/22 Truist
Norwegian Cruise Line upgraded to Buy at Truist amid bookings increase
09/20/22 Truist
Norwegian Cruise Line upgraded to Buy from Hold at Truist
09/19/22 Barclays
Norwegian Cruise Line price target raised to $16 from $14 at Barclays
09/06/22 Stifel
Norwegian Cruise Line liquidity concerns 'seem overblown,' says Stifel
GILD Gilead
/

+

09/20/22 Piper Sandler
Piper says Merck partial hold being lifted a positive update for Gilead
09/15/22 Truist
Gilead price target raised to $76 from $71 at Truist
09/13/22 Wells Fargo
Gilead price target raised to $74 from $63 at Wells Fargo
09/12/22 Piper Sandler
Gilead price target raised to $79 from $74 at Piper Sandler
LULU Lululemon
/

+

09/16/22 JPMorgan
Lululemon price target raised to $464 from $396 at JPMorgan
09/14/22 Jefferies
Lululemon long-term targets 'too aggressive,' says Jefferies
09/06/22 Barclays
Lululemon price target raised to $446 from $435 at Barclays
09/02/22 Jefferies
Jefferies says sell Lululemon on rally as Q2 is 'the peak'
LI Li Auto
/

+

09/06/22 Morgan Stanley
September 'crunch time' for China EV makers, says Morgan Stanley
08/29/22 Morgan Stanley
Li Auto delaying deliveries of L9, says Morgan Stanley
08/08/22 CLSA
Li Auto initiated with a Buy at CLSA
06/29/22 Morgan Stanley
Li Auto capital replenishment a strategic positive, says Morgan Stanley
APRN Blue Apron
/

+

08/10/22 Lake Street
Blue Apron initiated with a Buy at Lake Street
07/20/22 Benchmark
Benchmark starts Blue Apron at Buy with turnaround not getting credit
07/20/22 Benchmark
Blue Apron initiated with a Buy at Benchmark
05/10/22 Canaccord
Blue Apron price target lowered to $10 from $12 at Canaccord
WSM Williams-Sonoma
/

+

NCLH Norwegian Cruise Line
/

+

LULU Lululemon
/

+

LI Li Auto
/

+

GILD Gilead
/

+

APRN Blue Apron
/

+

AMLX Amylyx
/

+

  • 07
    Jan
NCLH Norwegian Cruise Line
/

+

LULU Lululemon
/

+

LI Li Auto
/

+

GILD Gilead
/

+

APRN Blue Apron
/

+

AMLX Amylyx
/

+

WSM Williams-Sonoma
/

+

NCLH Norwegian Cruise Line
/

+

LULU Lululemon
/

+

LI Li Auto
/

+

GILD Gilead
/

+

APRN Blue Apron
/

+

AMLX Amylyx
/

+

WSM Williams-Sonoma
/

+

QUAD Quad/Graphics
/

+

NCLH Norwegian Cruise Line
/

+

LULU Lululemon
/

+

LI Li Auto
/

+

GILD Gilead
/

+

AVCT AVCtechnologies
/

+

APRN Blue Apron
/

+

AMLX Amylyx
/

+

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.